David Ledbetter is chief clinical officer of Dascena, a personalized medicine company.
David Ledbetter
Chief clinical officer
Dascena
From this contributor
There are no autism-specific genes, just brain genes
There is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions, including intellectual disability.

There are no autism-specific genes, just brain genes
Developmental disorders should be viewed as continuum
Intellectual disability, autism, epilepsy and schizophrenia should be considered part of a spectrum of developmental brain dysfunction, says David Ledbetter.

Developmental disorders should be viewed as continuum
Explore more from The Transmitter
Meet the Autism Data Science Initiative grantees
The awarded projects plan to study gene-and-environment interactions in people, stem cells and organoids, as well as predictors of positive life outcomes in autistic youth and adults.

Meet the Autism Data Science Initiative grantees
The awarded projects plan to study gene-and-environment interactions in people, stem cells and organoids, as well as predictors of positive life outcomes in autistic youth and adults.
Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.

Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.
Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.

Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.